Sunday, June 22, 2025

FedEx Earns CEIV Pharma Corporate Certification for Guangzhou and Kansai Hubs, Reinforcing Leadership in Asia-Pacific Healthcare Logistics

Share

FedEx Express, a subsidiary of FedEx Corp. and one of the world’s largest express transportation companies, has announced that its Guangzhou (CAN) and Kansai (KIX) hubs have been awarded the prestigious CEIV Pharma Corporate Certification from the International Air Transport Association (IATA).

This dual recognition marks a major milestone in FedEx’s commitment to compliance, quality assurance, and global leadership in pharmaceutical logistics, particularly within the fast-growing Asia-Pacific region.

The CEIV Pharma Certification is globally recognized for ensuring the highest standards in the transportation and handling of temperature-sensitive healthcare products, including pharmaceuticals and vaccines. This corporate-level certification confirms FedEx’s robust quality management systems, operational excellence, and ability to meet the stringent regulatory demands of the healthcare and life sciences sector.

Kawal Preet, President, Asia Pacific, FedEx Express, commented:
“Healthcare innovation demands smarter, faster, and more resilient supply chains. As Asia Pacific rapidly emerges as a global hub for clinical trials and biopharma manufacturing, secure, compliant, and tech-enabled logistics are more critical than ever. Our AI-powered, cold-chain logistics solutions ensure product integrity and regulatory compliance, delivering peace of mind to customers.”

FedEx’s Advanced Pharma Logistics Capabilities Include:

  • A global network of Life Science Centers in Singapore, Tokyo, Incheon, Mumbai, Memphis, and the Netherlands.
  • Over 130 cold-chain facilities worldwide, ensuring consistent temperature integrity throughout the supply chain.
  • Real-time monitoring and AI-driven logistics to support the most sensitive and critical healthcare shipments.
  • Time Critical Special Services (SpS) and customized solutions for biologics, vaccines, and clinical trials.

Asia-Pacific: A Growing Biopharma Hub

With the Asia-Pacific pharmaceutical logistics market projected to grow from USD 163 billion in 2025 to USD 225 billion by 2030 (CAGR: 6.68%), and the region contributing nearly 50% of global clinical trials, FedEx’s strategic investments support the next generation of healthcare innovation.

The CEIV Pharma certification at CAN and KIX solidifies FedEx’s role in delivering safe, reliable, and regulatory-compliant pharmaceutical logistics in one of the world’s most vital healthcare corridors.

Read more

Local News